On September 1, China Isotope & Radiation Corporation (CIRC) signed an exclusive distribution agreement with Bayer.
According to the agreement, Bayer will grant CIRC the exclusive right to sell Xofigo® (radium chloride [223Ra] injection) in China.
Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.